期刊
FRONTIERS IN IMMUNOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.00223
关键词
cancer immunotherapy; immune checkpoints; sensitization; tumor microenvironment; PD-1; CTLA4; biomarkers; systems biology
类别
资金
- Children's Leukemia and Cancer Research Foundation
- Sock it to Sarcoma! Foundation
- Western Australian Cancer and Palliative Care Network fellowship
- NHMRC RD Wright Fellowship
- Simon Lee Fellowship
- Cancer Council of Western Australia
- NHMRC Centre of Research Excellence grant [1107043]
- National Health and Medical Research Council of Australia [1107043] Funding Source: NHMRC
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, providing remarkable clinical responses in some patients. However, the majority of patients do not respond. It is therefore crucial both to identify predictive biomarkers of response and to increase the response rates to immune checkpoint therapy. In this review we explore the current literature about the predictive characteristics of the tumor microenvironment and discuss therapeutic approaches that aim to change this toward a milieu that is conducive to response. We propose a personalized biomarker-based adaptive approach to immunotherapy, whereby a sensitizing therapy is tailored to the patient's specific tumor microenvironment, followed by on-treatment verification of a change in the targeted biomarker, followed by immune checkpoint therapy. By incorporating detailed knowledge of the immunological tumor microenvironment, we may be able to sensitize currently non-responsive tumors to respond to immune checkpoint therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据